Chloroquine phosphate: therapeutic drug for COVID-19.
10.12122/j.issn.1673-4254.2020.04.22
- Author:
Liqian MO
1
;
Ping ZHENG
1
Author Information
1. Department of Pharmacy, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
- Publication Type:Clinical Trial
- Keywords:
antiviral;
chloroquine phosphate;
coronavirus disease 2019;
pharmacokinetics;
safety
- MeSH:
Antiviral Agents;
Betacoronavirus;
drug effects;
China;
Chloroquine;
analogs & derivatives;
therapeutic use;
Coronavirus Infections;
drug therapy;
Humans;
Pandemics;
Pneumonia, Viral;
drug therapy
- From:
Journal of Southern Medical University
2020;40(4):586-594
- CountryChina
- Language:Chinese
-
Abstract:
Since the outbreak of coronavirus disease 2019 (COVID-19) in the late 2019, a variety of antiviral drugs have been used in the first-line clinical trial. The Diagnostic and Treatment Protocol for COVID-19 (Trial Version 6) in China recommends chloroquine phosphate for the first time as an anti-coronavirus trial drug. As a classic drug for treatment of malaria and rheumatism, chloroquine phosphate has been used clinically for more than 80 years, and has also shown good results in the treatment of various viral infections. As the plasma drug concentration varies greatly among different races and individuals and due to its narrow treatment window, chloroquine in likely to accumulate in the body to cause toxicity. Among the treatment regimens recommended for COVID-19, reports concerning the safety of a short-term high-dose chloroquine regimen remain scarce. In this review, the authors summarize the current research findings of chloroquine phosphate in the treatment of COVID-19, and examine the pharmacokinetic characteristics, antiviral therapy, the therapeutic mechanism and safety of chloroquine.
